Ocular to Submit Wet AMD Drug NDA in Q4, Eyeing Major Market Share
16h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
ocular-therapeuticwet-amd
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Ocular Therapeutic announced on 17 June 2026 that it will submit a New Drug Application (NDA) for its wet age-related macular degeneration (AMD) candidate, Axpaxli, in the fourth quarter of this year. The submission will target a blockbuster market currently dominated by Regeneron Pharmaceuticals and Roche, with the global wet AMD treatment market valued at approximately $12 billion. Advanced Micro Devices (AMD), the semiconductor ticker unrelated to the disease but relevant for investor context, was trading at $529.71 as of 13:30 UTC today. U.S. equity markets showed broad weakness, with the Nasdaq Composite down over 1.5% in morning trading, reflecting a risk-off sentiment that often pressures speculative biotech names ahead of key regulatory catalysts.
The wet AMD treatment landscape has been static for years, dominated by anti-VEGF injections from Regeneron's Eylea and Roche's Lucentis and Vabysmo. The last major new drug class approval for wet AMD was Roche's Vabysmo (faricimab) in January 2022, which offered an extended dosing interval. The current macro backdrop for biotech is challenging, with the SPDR S&P Biotech ETF (XBI) down 4% year-to-date against a flat S&P 500, as higher interest rates compress valuations for development-stage companies. The catalyst for Ocular's accelerated timeline is likely positive Phase 3 data readouts for Axpaxli, which reportedly demonstrated non-inferiority to standard of care on visual acuity gains with a potentially superior durability profile. This durability claim addresses the primary burden of current therapies: frequent, invasive intravitreal injections required every 4 to 12 weeks.
The financial stakes are immense. The global market for wet AMD therapies exceeds $12 billion annually. Regeneron's Eylea franchise alone generated $9.66 billion in global net product sales in 2025. Roche's Vabysmo, its newest entrant, posted sales of $3.48 billion in its first full year. For context, the entire U.S. ophthalmic pharmaceutical market is projected to reach $38 billion by 2028, according to Grand View Research. The competitive pressure is evident in recent pricing moves; the list price for a single dose of Eylea in the U.S. is approximately $1,850, while Vabysmo is priced around $2,200 per dose. A successful Axpaxli launch could capture a significant portion of this market, with analyst projections for peak sales ranging from $2 billion to $5 billion, contingent on its final label and head-to-head efficacy data. The XBI biotech index was trading near $82.50, a 22% decline from its 52-week high, highlighting the sector's valuation pressures.
| Metric | Value | Context |
|---|---|---|
| Global Wet AMD Market | ~$12B | Annual sales for all therapies |
| Eylea 2025 Sales | $9.66B | Regeneron's flagship product revenue |
| Vabysmo 2025 Sales | $3.48B | Roche's newest anti-VEGF |
| Projected Axpaxli Peak Sales | $2B-$5B | Analyst estimates, contingent on approval |
An Axpaxli approval would directly pressure incumbent leaders Regeneron (REGN) and Roche (RHHBY). Regeneron derives over 60% of its total revenue from Eylea, making it highly vulnerable to market share erosion. Secondary beneficiaries include companies like Alcon (ALC) and Bausch + Lomb (BLCO), which could see increased demand for drug delivery devices and surgical supplies used in retina care. A key limitation for Axpaxli is the ongoing shift toward longer-acting therapies and gene therapies; companies like Adverum Biotechnologies (ADVM) and Regenxbio (RGNX) are developing one-time gene treatments that could render even durable injectables obsolete in the long term. Institutional flow data from the past quarter shows hedge funds have been building short positions in Regeneron while accumulating long positions in smaller, late-stage ophthalmology names like Ocular, betting on a disruption of the status quo. The potential for pricing pressure in the anti-VEGF class is significant, which could compress gross margins for the dominant players by 300 to 500 basis points over a multi-year period.
The primary catalyst is the formal NDA submission in Q4 2026, which will trigger a standard 10-month FDA review clock for a potential approval decision by Q3 2027. Investors should monitor the Prescription Drug User Fee Act (PDUFA) date announcement following submission. Key levels for Ocular's stock are the $25 support level, which has held through recent market volatility, and the $38 resistance level from its 2025 highs. For Regeneron, watch the $950 support level; a sustained break below could signal deepening concerns over Eylea's long-term outlook. The next major ophthalmology conference, the American Academy of Ophthalmology annual meeting in November 2026, will likely feature detailed Axpaxli data presentations and potential commentary from key opinion leaders that could shift sentiment. Advisers are also watching Medicare reimbursement decisions for 2027, as any changes to the buy-and-bill model for physician-administered drugs could impact the commercial rollout strategy for all players in the space.
Wet AMD is an advanced form of macular degeneration where abnormal blood vessels grow under the retina and leak fluid, causing rapid central vision loss. It accounts for approximately 10-15% of AMD cases but is responsible for 90% of severe vision loss from the disease. Current standard of care involves repeated injections of drugs called anti-VEGF agents into the eye to inhibit blood vessel growth. Over 1.6 million Americans are affected, with the prevalence expected to rise with an aging population.
While detailed mechanism data is pending full publication, Axpaxli is believed to be a novel bispecific antibody targeting both VEGF and another pathway involved in angiogenesis and vascular leakage, such as angiopoietin-2 (Ang-2). This dual inhibition aims to provide more comprehensive disease control. In contrast, Eylea solely inhibits VEGF-A. Roche's Vabysmo also uses a dual-target approach (VEGF-A and Ang-2), so Axpaxli's potential differentiation may lie in its molecular structure, binding affinity, or its formulation designed for extended duration in the eye.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.